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approved therapies for its beneﬁ ciaries far advancing the national health basket. 
GOALS: The current work describes trends in MHS medication use and expenditures
over the last decade. OUTCOMES ITEMS USED IN THE DECISION: Total number
of packages dispensed per beneﬁ ciary, total drug expenditure. IMPLEMENTATION
STRATEGY: The MHS database was explored to identify trends in medication 
use and expenditures during the years 1998 to 2007. Expenditures were matched to 
the Israeli 2007 cost-of health living. Eight major pharmacological groups accounted
for half of the costs and were further detailed: antibiotics (representing “acute
therapy”), oncology drugs (for “severely ill”), cardiovascular, diabetic, lipid lowering
drugs and anti-depressive medications (for “chronic patients”), and medication to
treat migraine and asthma (“seasonal” therapies). RESULTS: During the study period 
MHS beneﬁ ciaries increase by 34.5% up to 1.74 million people. In this period rise of 
23% in total number of packages dispensed per beneﬁ ciary was noted. The most
noticeable rise in this parameter was noted in hypo-lipemic agents (394%), while the
most noticeable drop was noted in antibiotics (21%). In between, a rise of 84% was 
noticed on anti-neoplastic agents. During this period, 62% rise in total drug expendi-
ture (21% after correction for increased number of beneﬁ ciaries) was observed. The 
relative share of expenses of the 8 pharmacological groups was signiﬁ cantly changed,
with most noticeable rise of 454% in anti-neoplastic agents and 60% drop in antibiot-
ics. The total expenses on hypol-ipemic agents rose by 72%. LESSONS LEARNED:
The signiﬁ cant rise in medications use and expenses during the study period reﬂ ects 
changes in several parameters such as more aggressive treatment targets, better educa-
tion of physicians and patients, implementation of pre-authorization techniques and
introduction of newly developed, expensive medications. If continues, the dramatic 
rise in the share of expenses on anti-neoplastic drugs in MHS, as in other health care
givers in developed countries, could become a threat to the public health funding,
who’s budgets are limited, but in the long run could threat the drug manufacturers as
well. Discussions between health care givers, regulatory authorities and drug manu-
facturers in order to agree upon “rules of play” reﬂ ecting mutual interests are neces-
sary to resolve this threat.
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RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA)
UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A
MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING
Lafeuille MH1, Bailey R2, Vekeman F1, Piech CT2, McKenzie RS2, Lefebvre P1
1Groupe d’Analyse, Ltée, Montréal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, 
Horsham, PA, USA
OBJECTIVES: With recent changes in ESA prescribing information and coverage
limitations, this study evaluated current epoetin alfa (EPO) and darbepoetin alfa 
(DARB) real-world utilization in cancer chemotherapy patients in two different large, 
US outpatient settings. METHODS: Medical claims from the Ingenix IMPACT 
Managed Care and PREMIER Perspective Comparative Hospital databases, between 
2006Q1–2007Q4 were analyzed. Patients were q18 years old, had q1 cancer diagno-
sis, newly initiated on EPO or DARB with q2 doses of either drug as outpatients, and
received chemotherapy during ESA treatment. Mean cumulative dose was used to 
assess impact of ESA prescribing information changes on drug utilization over time. 
The EPO : DARB dose ratio was calculated from the mean cumulative dose of EPO
and DARB. RESULTS: A total of 16,555 ESA treatment episodes (IMPACT:9,301; 
PREMIER:7,259) were identiﬁ ed. Patients receiving EPO were slightly older in 
IMPACT (EPO: 58.4 years; DARB: 56.3 years, p  0.0001) and slightly younger in 
PREMIER (EPO: 62.7 years; DARB: 64.0 years, p  0.0001), compared to DARB. A 
lower proportion of women was observed for the EPO groups (IMPACT: 64.2% vs.
68.4%; PREMIER: 62.2% vs. 65.4%, p  0.05 for both). The overall cumulative dose
per treatment episode was EPO 317,954 Units and DARB 1,238 mcg for IMPACT 
and EPO 263,582 Units and DARB 1,005 mcg for PREMIER, corresponding to
similar dose ratios of 257:1 and 262:1 for the managed care and hospital outpatient 
settings, respectively. Over time, mean treatment duration and cumulative ESA dose 
presented a downward trend for both EPO and DARB groups in both settings, with
dose ratios decreasing from 258:1 to 227:1 in IMPACT and from 279:1 to 209:1 in
PREMIER between 2006Q1 and 2007Q4. CONCLUSIONS: This study of cancer 
patients receiving chemotherapy in two outpatient settings reported decreased ESA 
utilization and EPO: DARB dose ratios following recent changes to ESA prescribing 
information and coverage.
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WHEN IS CANCER CARE COST-EFFECTIVE? A SYSTEMATIC
OVERVIEW OF COST-UTILITY ANALYSES IN ONCOLOGY
Greenberg D1, Earle C2, Fang C1, Eldar-Lissai A3, Neumann PJ1
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OBJECTIVES: New cancer treatments pose a substantial ﬁ nancial burden on patients,
their families, and society as a whole. Cost-utility analyses (CUAs) provide necessary 
information on the value for money and are widely published in the medical and
economic literature. We describe the growth over time of cancer-related CUAs 
and investigate whether methodological quality has improved. METHODS: We sys-
tematically searched the English-language literature for original cancer-related CUAs 
published through 2006 using Medline and other databases. Two trained readers
independently audited each study and collected data on a variety of elements related
to study origin, methods, and reporting of results. RESULTS: We identiﬁ ed 200 cancer-
related CUAs (currently included in the Tufts Medical Center Cost-Effectiveness 
Analysis Registry; www.cearegistry.org). The average annual number of studies has 
increased from 7 during 1988–2001 to 22 during 2002–2006. Leading sites studied
were breast (34%), colorectal (12%), and hematological (12%) cancers. Studies
have pertained to the U.S. (53%) U.K. (10%), The Netherlands (8%), and Canada 
(7%) and examined interventions for tertiary care (71%), secondary prevention
(22%), and primary prevention (7%). The pharmaceutical industry funded 25%
of studies, 41% were funded by non-industry sources and 32% did not disclose
any funding source. The median reported cost-effectiveness ratio (2007 values) 
was $32,000 for breast cancer, $17,000 for colorectal cancer, and $39,500 for hema-
tological cancers. Although adherence to recommended methods has somewhat 
improved in recent years, the average quality of studies (on a 1–7 Likert scale) 
was 4.2(o 1.1) and did not change substantially. CONCLUSIONS: The economic 
impact of cancer related interventions has received increased attention in the medical 
literature due to the very high cost of many newer cancer drugs. The lack of change 
in the quality of published studies suggests that journals should adopt a more rigorous
review to help ensure that authors adhere to guidelines for conducting and reporting 
CUAs.
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ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH 
CARE COSTS ASSOCIATED WITH COLORECTAL CANCER
Rahman M1, Weinstein R2, Wilcox M2, Matcho A2, Wong S1
1Ortho Clinical Diagnostics, Raritan, NJ, USA, 2PRD USA, Titusville, NJ, USA
OBJECTIVES: This burden of illness study was conducted to assess the 12-month
resource utilization and health care costs, along with the major drivers of those 
costs, associated with an incident diagnosis of colorectal cancer (CRC). METHODS:
An analysis of incident CRC patients identiﬁ ed using a claims database, was per-
formed, for 2005, 2006, and 2007. CRC patients and the age and gender matched
comparator group (1:4) for each year, were required to have continuous enrollment 
in a plan and no CRC diagnoses during the 18 months prior to the ﬁ rst diagnosis 
of CRC in the year. The CRC and comparison groups were each described in terms 
of their health care service use and health care costs, which were compared, using
nonparametric Wilcoxon rank-sum tests, with mean values reported here for 2007. 
RESULTS: There were 13,673 patients diagnosed with CRC in 2007, in this database,
and we selected 54,688 controls. The mean health care cost for these patients 
diagnosed with CRC was $36,558 vs. $6,407 for controls; p  0.001. The primary 
drivers for this nearly 6 times greater cost difference between the 2 groups were: hos-
pitalizations ($15,996 vs. $1,959; p  0.001); prescription drugs ($6,689 vs. $1,382; 
p  0.001); radiology tests ($2,312 vs. $333; p  0.001); and physician visits ($1,665 
vs. $617; p  0.001). Resource utilization over the 12-month period showed that 
the patients with CRC, when compared to the control group, had a signiﬁ cantly
greater (p  0.001) mean number of hospitalizations (0.9 vs. 0.2); prescriptions drugs 
(33 vs. 17); radiology tests (9 vs. 2); and physician visits (12 vs. 7). The results were
similar for analyses conducted on 2006 and 2005 data. CONCLUSIONS: The signiﬁ -
cantly higher 12-month resource utilization and health care costs noted in patients
diagnosed with CRC, compared to age and gender matched controls, are primarily
driven by an increased need for hospitalizations, prescription drugs, radiology tests, 
and physician visits.
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SURVIVAL IN FOLFOX OR FOLFIRI TREATED STAGE IV COLORECTAL 
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OBJECTIVES: The trade-off between cost and mortality among stage IV colorectal 
cancer patients treated with 5FU/leucovorin/oxaliplatin (FOLFOX) or 5FU/leucovo-
rin/irinotecan (FOLFIRI) was examined. Multiple linked data sources were necessary
to obtain treatment, cancer stage, cost, and mortality. METHODS: Adults with 
colorectal cancer newly treated with FOLFOX or FOLFIRI were identiﬁ ed from a 
claims database for services January 1, 2002-December 31, 2005. Privacy board
approval for waiver of patient consent was obtained, and cancer stage was abstracted
from medical records; death was obtained from the National Death Index. Once 
matched, 41 FOLFOX and 86 FOLFIRI patients had stage IV cancer and were
retained. Costs were analyzed using generalized linear modeling; mortality was 
modeled using Cox proportional hazards analysis. Both controlled for age, gender, 
region, comorbidities, and treatment (biologic use, surgery, radiation). Sensitivity
analysis of cost was performed to adjust for availability of generic irinotecan in 2008.
Relative value of FOLFOX and FOLFIRI was measured by an incremental cost-effec-
tiveness ratio (ICER). Conﬁ dence intervals were estimated by bootstrapping with 1000 
replications. RESULTS: Unadjusted annualized mean cost was $152,213 (95% conﬁ -
dence interval [CI]: $113,547–$190,878) for FOLFOX, $107,994 (95% CI: $92,356–
$123,632) for FOLFIRI. Death occurred among 5 (12%) FOLFOX and 42 (53%) 
FOLFIRI patients. Adjusted analysis found no statistical difference in cost between 
cohorts. Cox analysis found signiﬁ cant survival advantage for FOLFOX compared to
FOLFIRI (Hazard ratio  5.2; 95% CI: 1.7–15.8). Biologic agent use was higher in 
the FOLFOX cohort and was associated with survival. ICER found one additional 
life-year saved was $1,236 (95% CI $300–$2350) with FOLFOX compared to 
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FOLFIRI. CONCLUSIONS: FOLFOX appears to have favorable cost effectiveness 
compared to other agents in the treatment of stage IV colorectal cancer, even after 
factoring in the impact of generic irinotecan.
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PHYSICAL FUNCTION AND THE CONCOMITANT USE OF
ANTICHOLINERGIC ANTIHISTAMINES AND CHOLINESTERASE 
INHIBITORS AMONG MEDICAID RECIPIENTS WITH DEMENTIA
Modi A1, Craig B1, Weiner M2, Sands L1, Thomas J1
1Purdue University, West Lafayette, IN, USA, 2Indiana University, Indiana University Center for 
Aging Research and Regenstrief Institute Inc, Indianapolis, IN, USA
OBJECTIVES: Antihistamines with anticholinergic properties (AA) are often used to
treat comorbidities in patients with dementia. Use of AA with cholinesterase inhibitors 
(CHI) may counteract beneﬁ ts of CHI in improving activities of daily living (ADL) or 
slowing ADL decline. Associations between use of AA with CHI and ADL function 
were assessed. METHODS: A retrospective cohort analysis of Indiana Medicaid 
claims and enrollment data from July 2001 through December 2005 merged with 
Minimum Data Set (MDS) identiﬁ ed persons q65 years, with dementia based on previ-
ously assessed criteria for identifying dementia and, receiving CHI. Persons taking 
anticholinergics other than AA during the study interval from ﬁ rst to last MDS assess-
ment during CHI use were excluded. Piecewise repeated measures analysis used days 
taking AA and days not taking AA during each assessment interval as predictors to
estimate inﬂ uence of AA use on MDS ADL function scores (range 0–28, higher scores 
 more dependence). Presence of shifts in curves and changes in slopes deﬁ ned changes 
in ADL. Age, gender, race, region, marital status and number of medications taken at 
the start of CHI use, Charlson comorbidity score and propensity score for receipt of 
AA were included as ﬁ xed covariates. RESULTS: A sample of 2,690 persons with 
mean age of 82 years, 75% female and, 90% white was identiﬁ ed. Of these, 691 
(26%) used AA. Overall, a 0.45 (p  0.02) upward shift in ADL score indicated an
immediate decrease in ADL function with AA use. Among persons with moderate 
ADL dependence (score 6–12), an increase in slope of 0.53 (p  0.04) per quarter also
was observed indicating faster decline with AA use. CONCLUSIONS: Use of AA with 
CHI is associated with greater ADL decline in Medicaid recipients with dementia. 
Potential impact of AA use on physical function should be considered before prescrib-
ing AA with CHI.
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RACIAL DIAPARITIES AND BARRIER TO DRUG UTILIZATION IN
PATIENTS WITH DIABETES IN THE UNITED STATES
Seetasith A, Zhang JX
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: We sought to assess barriers to the appropriate statin usage measured
through out-of-pocket payment by insurance status and racial disparities in patients 
with diabetes. METHODS: We analyzed 1,708 civilian, non-institutionalized patients 
with diabetes aged between 20 and 85 in the 2003 Medical Expenditure Panel 
survey (MEPS), a nationally representative survey in the United States which was 
linked to drug utilization ﬁ les. We categorized patients with diabetes into six mutually
exclusive insurance groups. We performed bivariate chi-square tests to assess the 
association between race and statins use, and insurance status and statin use during 
the year. We further performed multivariate logistic regression analysis to assess the 
effect of race/ethnicity on statin usage for patients of different races/ethnicity, control-
ling for socioeconomic variables, and co-morbid conditions. RESULTS: Among the 
population, 369 (21.6%) were African American, 66 (3.9%) Asian and 396 (23.2%)
were Hispanic; the mean out-of-pocket payment per prescription of statins was $61.4
(SD $62.5) for Medicare patients, $24.0 (SD $43.7) for Medicaid patients, $ 25.4 (SD
$49.0) for patients with dual eligibility, $35.2 (SD $33.5) for those with private insur-
ance, $76.7 (SD $47.8) for those without insurance, and $83.9 (SD $90.5) for others. 
In bivariate analysis, statin usage was found to be signiﬁ cantly different across races 
and insurance status (p  0.020 and p  0.0001, respectively). In multivariate regres-
sion analysis, compared to White patients, African American patients were less likely 
to use statin (adjusted OR 0.57, 95% CI 0.43–0.76, p  0.0001). Asian and Hispanic 
patients were marginally less likely to use statin (adjusted OR 0.60, 95% CI 0.34–
1.05, p  0.078; and adjusted OR 0.75, 95% CI 0.56–1.00, p  0.055, respectively). 
CONCLUSIONS: Drug utilization is associated with insurance coverage. Racial/eth-
nicity disparity is observed in drug utilization of patients with diabetes after adjusting 
for insurance status.
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PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH
CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE
ANALYSIS OF ADMINISTRATIVE CLAIMS DATA
Vekeman F1, Laliberte F1, Afonja O2, Lafeuille MH1, Barghout V2, Duh MS3, Skarin AT4
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OBJECTIVES: Pegﬁ lgrastim is a long-acting granulocyte colony-stimulating factor 
(G-CSF) used to prevent or treat febrile neutropenia associated with myelosuppressive
anticancer therapies. According to the prescribing information, pegﬁ lgrastim should
not be administered within 14 days before or 24 hours after cytotoxic chemotherapy 
because of the potential for myeloid toxicity. This study examined use patterns of 
pegﬁ lgrastim in real-life practice. METHODS: Analysis of health insurance claims
data in 2000–2007 from 35 large health plans across the US was conducted. Patients 
who had a cancer diagnosis and chemotherapy within 120 days of their ﬁ rst pegﬁ l-
grastim injection were identiﬁ ed. The proportion of pegﬁ lgrastim injections that were
followed by administration of chemotherapy within 11 and 9 days was calculated.
Analysis was also stratiﬁ ed by cancer type [Non-Hodgkin’s lymphoma (NHL), lung, 
and breast]. RESULTS: A total of 13,526 cancer patients received 57,118 pegﬁ lgrastim 
injections. NHL, lung, and breast cohorts comprised 2,722, 2,772, and 4,955 patients, 
respectively. Mean age (SD) was 55.0 (11.6) and women represented 65.9% of study
population. Among all cancer types, 19.2% of pegﬁ lgrastim injections had a chemo-
therapy claim within the following 11 days. This pattern of use was the highest in 
NHL (18.9%), followed by lung (17.1%), and breast (16.2%). Similar results were 
observed in the 9-day sensitivity analysis (all cancer: 16.2%, NHL: 17.4%, lung: 
16.0%, breast: 14.7%). CONCLUSIONS: Based on the retrospective analysis of this 
administrative claims database, the use of pegﬁ lgrastim within 11 days of an admin-
istration of chemotherapy was observed in 15–20% of cases which is inconsistent with
the recommended guidelines. Pegﬁ lgrastim use in these situations may have the poten-
tial to increase sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy.
Further research is being conducted to assess the related clinical and economic impact 
of this pattern of usage.
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PERSONALIZED MEDICINE: FACTORS INFLUENCING REIMBURSEMENT
Meckley LM, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: Personalized medicine (PM) has attracted tremendous interest, but 
yielded few marketed products. We examined factors inﬂ uencing the approval, cover-
age, and reimbursement of existing PM technologies. METHODS: We conducted six 
case studies of paired genetic tests and treatments in order to develop a framework 
to explain differences in adoption and reimbursement. We divided these case studies 
into three groups based on the purpose of the PM technology: Disease differentiation 
(HER2/neu with Herceptin (trastuzumab), hepatitis C genotyping with ribavirin/
pegylated interferon, and Oncotype DX with chemotherapy); pharmacogenetics
(UGT1A1 with irinotecan (Camptosar) and VKORC1/CYP2C9 with warfarin) and 
predisposition tests (BRCA 1/2 with prophylactic surgical measures and Oncotype DX
with chemotherapy). RESULTS: The factors inﬂ uencing approval, coverage and reim-
bursement appear based broadly on the purpose of, and evidence for, the PM technol-
ogy, rather than the type of device regulation (i.e., PMA, CLIA or 510(k)). Disease
differentiation test reimbursement is more widespread than other PM tests because 
of better evidence, guidelines, and clinician preferences. Predisposition tests may be 
reimbursed, despite the lack of randomized clinical trials, because people may value
the information from testing, regardless of the clinical consequences. Pharmacogenet-
ics (PGx) faces reimbursement hurdles because of the lack of evidence about clinical 
utility, though some companies bypass payers, and market PGx tests directly to con-
sumers. An additional challenge for all PM is the cumbersome existing coding system 
for reimbursement and the lack of value-based arrangements. CONCLUSIONS: To 
date, the promise and hype of PM has outpaced its evidentiary support. In order to
achieve favorable coverage and reimbursement and to support premium prices for
PM, manufacturers will need to bring better clinical evidence to the marketplace 
and develop better support for the value of their products. More ﬂ exible reim-
bursement systems are needed to reward PM technologies that demonstrate evidence
of value.
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IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING
ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS
Hughes DA1, Al-Zubiedi S2, Hanson A2, Jorgensen A2, Pirmohamed M2
1Bangor University, Bangor, UK, 2University of Liverpool, Liverpool, UK
OBJECTIVES: The anticoagulant effect of warfarin is subject to wide dose variability
that may lead to hemorrhagic and thrombotic events. Variations in the CYP2C9 and 
VKORC1 genes together with clinical factors explain approximately 50% of this 
variability. The aim was to estimate the health care resource use, and overall costs
associated with therapy from the perspective of the UK NHS. METHODS: As part 
of a 6-month prospective cohort study evaluating pharmacogenetic and clinical factors 
associated with warfarin therapy, patients’ use of resources were recorded and costs
valued (UK a for 2006/7). Resource use was compared among patient sub-groups
(deﬁ ned by age; gender; CYP2C9 genotype; VKORC1 genotype; adverse events; co-
medication; co-morbidities; and smoking status). Mean costs were calculated with
95%CI estimated using non-parametric bootstrap sampling. RESULTS: Complete 
data were available for 254 patients. During the study period a total of 930 antico-
agulation visits (median 3 per patient, IQR 1, 5) and 4059 INR measurements (median 
15, IQR 10, 20) were recorded. Of the 70 patients who had experienced an adverse 
event, 16 (6.3%) required hospitalisation. Controlling for age, gender, and co-morbidi-
ties in patients who experienced an adverse event, the OR for hospitalization was 8.35 
